IGM Biosciences, Inc. (IGMS)

Market Cap	410.30M
Revenue (ttm)	2.92M
Net Income (ttm)	-219.84M
Shares Out	59.46M
EPS (ttm)	-3.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	215,228
Open	6.88
Previous Close	7.05
Day's Range	6.76 - 7.50
52-Week Range	6.17 - 22.50
Beta	0.01
Analysts	Buy
Price Target	17.43 (+152.61%)
Earnings Date	Nov 8, 2024

About IGMS

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 prote...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 18, 2019
• Employees: 224
• Stock Exchange: NASDAQ
• Ticker Symbol: IGMS
• Website: https://igmbio.com

Financial Performance

In 2023, IGM Biosciences's revenue was $2.13 million, an increase of 99.25% compared to the previous year's $1.07 million. Losses were -$246.42 million, 11.4% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for IGMS stock is "Buy." The 12-month stock price forecast is $17.43, which is an increase of 152.61% from the latest price.

Price Target

$17.43

(152.61% upside)

Analyst Consensus: Buy